Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-12-19

FDA Approved: ENVARSUS XR — Supplemental Application (Veloxis Pharmaceuticals, Inc)

View source ↗

Summary

The FDA approved a supplemental application for ENVARSUS XR (Tacrolimus) submitted by Veloxis Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Envarsus XR (Tacrolimus)

Snippet

SUPPL AP for ENVARSUS XR (TACROLIMUS)